Thomas Grogan,Hiro Nitta,Michael Barnes,Penny Towne,Shalini Singh,June F. Clements,Crystal Schemp,Esteban Roberts
申请号：
US15475668
公开号：
US20170205416A1
申请日:
2017.03.31
申请国别(地区):
US
年份:
2017
代理人:
摘要：
Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.
